Exposure to semaglutide for all alternative treatment arms was reduced by more than 50% compared with the exposure observed following an overnight fast in the reference arm (night30 min), even when subjects fasted for 6 h prior to dosing (6 h30 min treatment arm) (Fig
These treatments should be offered to adults who meet all of the following: At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) BMI of 35 kg/m or above (or 32.5 kg/m or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) Access to a specialist weight management service that provides multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions Treatment is typically time-limited to up to 2 years Previous unsuccessful attempts at weight loss through lifestyle measures alone Orlistat may be considered for adults with a BMI of 28 kg/m or above with associated risk factors (such as type 2 diabetes or cardiovascular disease), or 30 kg/m or above without additional risk factors
Potential UK Access Pathways Once approved, UK access may follow several routes: NHS specialist weight-management pathways diabetes and metabolic clinics private UK weight-loss clinics licensed prescribers online medical services via regulated telehealth Because the retatrutide peptide targets three metabolic pathways, NHS evaluation may prioritize individuals with severe obesity or strong medical need
It is worth noting that attribution of symptoms can be challenging when using multiple products
Romestaing C, Julliard AK
Results of follow-up at 8 years
.png)
